Barinthus (BRNS) Director Alex Hammacher Sells/Disposes 114,819 Shares

What Happened
Alex Hammacher, a director of Barinthus Biotherapeutics plc (BRNS), reported dispositions totaling 114,819 ordinary shares (or equivalent ADS-based interests) on September 9, 2026. Transactions listed: 3,000 shares (N/A proceeds) and six derivative-related disposals of 34,328; 18,604; 19,197; 19,516; and 20,174 shares each reported at $0.00 proceeds. These were merger-related dispositions tied to the issuer’s acquisition by Beacon Topco/Topco and reflect conversion/assumption mechanics rather than open-market cash sales.

Key Details

• Transaction date: September 9, 2026 (Effective Time of the Scheme of Arrangement).
• Shares disposed: total 114,819 shares (3,000 + 34,328 + 18,604 + 19,197 + 19,516 + 20,174).
• Reported proceeds: most derivative disposals reported $0.00; one tranche (3,000) listed as N/A. Total cash proceeds not reported.
• Shares owned after transaction: not reported in the provided filing excerpt.
• Filing timeliness: Report period and filing date are the same (Sept 9, 2026), indicating a contemporaneous filing.
• Footnotes: F1 = ADS represent ordinary shares; F2–F4 = transactions were effected under a Merger Agreement/scheme—each Barinthus share converted into the right to receive 0.111 Topco common shares and outstanding options were converted/assumed by Topco.

Context
These dispositions are merger-related corporate actions: ordinary shares and options were converted or assumed as part of the Topco acquisition, which explains the $0 or N/A proceeds reported. This is different from an open-market sale and should be read as a structural change in ownership/holding form due to the merger, not necessarily as a trading signal about the company’s prospects.